Incyte Corp (NAS:INCY)
$ 57.05 0 (0%) Market Cap: 12.83 Bil Enterprise Value: 9.01 Bil PE Ratio: 17.29 PB Ratio: 2.38 GF Score: 86/100

Incyte Corp at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 12:30PM GMT
Release Date Price: $93.32 (-0.54%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

Good morning, and Happy New Year. Welcome to the 39th Annual, and first and hopefully only time, Virtual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst. And it's my pleasure to introduce Hervé Hoppenot, the Chairman and CEO of Incyte, our first company presenting today.

Please note that following Hervé's presentation, we will have a Q&A session right here in the same Zoom room. (Operator Instructions)

And so with that, let me turn things over to Hervé.

Herve Hoppenot
Incyte Corporation - Chairman, President & CEO

Thank you. Thank you, Cory. Welcome to this presentation, to everybody. Happy to speak about where we are at Incyte from -- here from Wilmington in Delaware. So I will be -- first, I need to say that I will be making forward-looking statement in the presentation, and I urge you to refer to the SEC document on our website.

So we are on Slide 3, and I will be using

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot